Pooling 17 in vitro studies using human-derived cell models, this meta-analysis found that GLP-1 receptor agonists — the drug class including semaglutide — significantly improved mitochondrial bioenergetics (SMD = 1.109, p < 0.001) and reduced mitochondrial reactive oxygen species (SMD = -3.489, p = 0.034), independent of their well-known systemic metabolic effects on appetite and glycemic control. Only 11 studies contributed quantifiable data; the effect on mitochondrial membrane potential remained non-significant in primary analysis.
The finding that GLP-1 RAs appear to act directly on mitochondria — rather than solely through downstream metabolic improvements — reframes these drugs from glucose-lowering agents into potential cellular energy modulators. This matters for longevity science, where mitochondrial dysfunction and elevated ROS are established drivers of aging, neurodegeneration, and cardiovascular decline. If confirmed in vivo, direct mitochondrial action could partially explain GLP-1 RA benefits observed in heart failure and Parkinson's disease trials beyond weight loss.
However, the evidence base here is fragile. The meta-analysis covers only 17 studies, certainty ratings are "very low" across primary outcomes due to substantial heterogeneity, publication bias, and methodological inconsistency between labs. In vitro human-derived models cannot replicate whole-body physiology or tissue-specific mitochondrial dynamics. This review is best characterized as hypothesis-generating — pointing toward a plausible mechanism warranting rigorous, standardized human tissue studies rather than clinical translation claims.
